India’s Apollo Hospitals Enterprise has reported consolidated profits after tax (PAT) of Rs2.54bn ($30.50m) in the fourth quarter (Q4) of fiscal 2024 (FY 2024), a 76% increase from Rs1.45bn in Q4 FY 2023.

Diluted earnings per share (EPS) for the quarter ending 31 March 2024 were Rs17.65, against Rs10.05 a year ago.

Revenue from operations amounted to Rs49.43bn in Q4 FY 2024, a 15% increase compared with Rs43.02bn in the same quarter last year.

Apollo Hospitals’ healthcare services (HCS) segment revenue increased 17% to Rs25.62bn in Q4 FY 2024, from Rs21.94bn in the prior year.

Apollo Health & Lifestyle Limited (AHLL), a wholly owned subsidiary, also reported a 15% year-on-year (YOY) increase in revenue of Rs3.55bn while the Pharmacy Distribution & Digital Health business revenue rose 13% to Rs20.27bn.

The group’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) for Q4 FY24 stood at Rs6.4bn, a 31% increase from Rs4.88bn a year ago.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This is after the cost of Apollo 247, which reached Rs15.08bn in Q4 FY 2024, with an Rs106m non-cash employee stock ownership plan (ESOP) charge.

For the full fiscal year 2024, Apollo Hospitals reported a consolidated PAT of Rs8.98bn, a 33% increase from Rs6.76bn in the prior year, excluding a deferred tax reversal of Rs1.43bn in FY 2023.

Revenue for FY 2024 was Rs190.59bn, a 15% growth from Rs166.12bn last year. Revenue for the HCS segment in FY 2024 totalled Rs98.67bn, up 14% from Rs86.76bn in the previous year.

The group’s EBITDA for FY 2024 increased 17% to Rs23.90bn from Rs20.49bn a year ago, after accounting for Apollo 247 costs of Rs7.07m in FY 2024, including a Rs891m non-cash ESOP charge.

As of 31 March 2024, Apollo operated 7,945 beds, excluding managed beds and those under AHLL, with 2,557 being new and 1,603 occupied.

The overall occupancy rate for the hospitals was at 65% at the end of this March, compared to 64% last year, driven by a strong increase in patient flows across the network.

Apollo Hospitals Group chairman Dr Prathap Reddy said: “Going forward, Apollo Hospitals will continue to strengthen its endeavours to identify and introduce best-in-class, technology-enabled healthcare solutions to enhance patient outcomes and improve access to quality care.”